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To examine the effect of maternal folic acid supplementation and maternal plasma folate and
antiepileptic drug (AED) concentrations on language delay in AED-exposed children of
mothers with epilepsy.
Methods
Children of mothers with and without epilepsy enrolled from 1999 to 2008 in the Norwegian
Mother and Child Cohort study were included. Information on medical history, AED use, and
folic acid supplementation during pregnancy was collected from parent-completed ques-
tionnaires. Maternal plasma folate andmaternal plasma and umbilical cord AED concentrations
were measured in blood samples from gestational weeks 17 to 19 and immediately after birth,
respectively. Language development at 18 and 36 months was evaluated by the Ages and Stages
Questionnaires.
Results
A total of 335 AED-exposed children of mothers with epilepsy and 104,222 children of mothers
without epilepsy were surveyed. For those with no maternal periconceptional folic acid sup-
plementation, the fully adjusted odds ratio (OR) for language delay in AED-exposed children
compared to the controls at 18 months was 3.9 (95% confidence interval [CI] 1.9–7.8, p <
0.001) and at 36 months was 4.7 (95% CI 2.0–10.6, p < 0.001). When folic supplementation
was used, the corresponding ORs for language delay were 1.7 (95% CI 1.2–2.6, p = 0.01) and
1.7 (95% CI 0.9–3.2, p = 0.13), respectively. The positive effect of folic acid supplement use on
language delay in AED-exposed children was significant only when supplement was used in the
period from 4 weeks before the pregnancy and until the end of the first trimester.
Conclusion
Folic acid use early in pregnancy may have a preventive effect on language delay associated with
in utero AED exposure.
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Most women with epilepsy are dependent on treatment with
antiepileptic drugs (AEDs) throughout their pregnancy to
prevent epileptic seizures.1 AEDs increase the risk of con-
genital malformations in a dose-dependent manner.2 Some
AEDs have also been associated with impaired neuro-
development and behavioral disorders in the offspring.1,2
Hence, it is crucial to identify factors that modulate the risk of
AED-related fetal harm.
Folate is a B vitamin important for normal brain de-
velopment.3 Many AEDs interact with folate metabolism and
have been associated with reduced plasma folate.4,5 There is
growing evidence of a positive association between maternal
folate status during pregnancy and neurodevelopmental out-
come in the offspring.3,6–8 Few studies have examined
whether folic acid supplementation protects against impaired
neurodevelopment after AED exposure in utero. Some studies
have indicated that folic acid may have a positive effect on IQ
and verbal abilities in children exposed to AEDs in utero,9,10
but the results are conflicting.11,12 We have previously found
that AED-exposed children have fewer autistic traits if their
mothers used folic acid supplements in the periconceptional
period.13 Women in Norway are recommended to use 0.4 mg
folic acid daily in the periconceptional period only, while
women with epilepsy who use AEDs usually are recom-
mended to use 1 to 5 mg daily in the periconceptional period
and 0.4 mg daily in the second and third trimesters. There is
no mandatory folic acid food fortification in Norway.14
The aim of our study was to investigate the effect of maternal
folic acid supplement use, maternal plasma folate, and AED
concentrations during pregnancy on language development in
AED-exposed children of mothers with epilepsy.
Methods
Study population
The study population consisted of women and children in-
cluded in the Norwegian Mother and Child Cohort Study
(MoBa). MoBa is a prospective, ongoing population-based
pregnancy cohort study conducted by the Norwegian In-
stitute of Public Health and is linked to the compulsory
Medical Birth Registry of Norway (MBRN).15 Norwegian-
speaking women were invited to participate from 1999 to
2008. The participation rate was 41%. Information on back-
ground, medical history, medication use, vitamin and folic
acid intake, and child development, including language
function, was obtained by parent-completed questionnaires.
The questionnaires were answered in gestational weeks
17 to 19 (Q1) and 30 (Q2) and when the child was 18 and 36
months old (Q3 and Q4; response rates, 72% and 56%, re-
spectively). Maternal blood samples were collected at week
17 to 19 of gestation and from the umbilical cord immediately
after delivery.
The epilepsy diagnosis is based on self-reported information
from the MoBa questionnaires and information from the
MBRN registered by the family doctor or midwife.16 We have
previously validated the epilepsy cohort in MoBa (data
available from Dryad, Methods, doi.org/10.5061/dryad.
1237b6m), and the validity was very good.17
Our material is based on version VIII of the MoBa databank
and consisted of 724 children of 616 mothers with epilepsy
and 104,222 children of 86,443 mothers without epilepsy with
available information on maternal folic acid supplement use
during pregnancy (figure 1). The children of mothers with
epilepsy were further classified into 2 groups: 1 group exposed
to AEDs in utero (n = 335), our main study group, and
another group not exposed to AEDs in utero (n = 389). We
have previously reported on general development after in
utero and breastmilk exposure to AED in this cohort.18,19
Variables
Maternal folic acid supplementation
Intake of folic acid before and during pregnancy was reported
in gestational week 17 to 19 (Q1) for the following time
intervals: >5 weeks before pregnancy, 4 weeks before preg-
nancy (preconception), and use during gestational weeks 0 to
4, 5 to 8, 9 to 12, and 13+. Folic acid use in gestational weeks
13 to 16, 17 to 20, 21 to 24, 25 to 29, and 29+ was reported in
gestational week 30 (Q2) (data available from Dryad, Meth-
ods, doi.org/10.5061/dryad.1237b6m). Folic acid doses were
obtained for 139 AED-exposed children and 160 AED-
unexposed children by a separate retrospective questionnaire
to women with epilepsy in our previous validation study (Q5;
response rate 50%).17 In 84 children (25%) in the AED-
exposed group and 21 children (5%) in the AED-unexposed
group, the mothers reported a daily intake of folic acid of
≥1 mg. We defined periconceptional folic acid use as maternal
intake of folic acid supplements from 4 weeks before the start
of the pregnancy and/or during the first trimester.
AED use
Information on AED use and type of medication was collected
from self-reported information in Q1 and the MBRN data
registered by the family doctor or midwife.15 There was 100%
agreement between self-reported AED use in MoBa and the
Glossary
AED = antiepileptic drug; AR = attributable risk; ASQ = Ages and Stages Questionnaires; CI = confidence interval; hmTHF =
4-alfa-hydroxy-5-methyltetrahydrofolate;MBRN = Medical Birth Registry of Norway;MoBa = Norwegian Mother and Child
Cohort Study; mTHF = 5-methyltetrahydrofolate; OR = odds ratio; RR = relative risk.
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reported AED use in hospital records in our previous vali-
dation study.17
Measurement of plasma folate and AED
concentrations
From the MoBa biobank,20 folate was available in maternal
plasma samples obtained at gestational week 17 to 19 for 228
AED-exposed children (68%). Analysis included the bi-
ologically active 5-methyltetrahydrofolate (mTHF) and the
degradation product 4-alfa-hydroxy-5-methyltetrahydrofolate
(hmTHF). mTHF represents the prevailing folate form in
plasma. This form is unstable in blood samples kept at room
temperature, but is largely recovered as hmTHF. Hence,
maternal plasma folate is given as the sum of the concentra-
tion of mTHF and hmTHF.21,22
The concentrations of valproate, lamotrigine, carbamazepine,
carbamazepine10,11-epoxide, levetiracetam, topiramate, and
the oxcarbazepine monohydroxy derivative metabolite were
analyzed in 226 maternal plasma samples obtained at gesta-
tional week 17 to 19 and in 198 samples from the umbilical
cord, as described previously,17 for a total of 255 AED-exposed
children (76%). In 238 of these samples (93%), the reported
AED was detected. For the statistical analysis, the plasma
concentrations were normalized relative to the ranges ob-
served within each group according to the following formula:
100 × (observed concentration − minimum concentration)/
concentration range.10,23 The mean of the normalized plasma
concentrations was calculated for each child on the basis of
both the concentration from the maternal sample and the
umbilical cord sample if both were present. If only one of the
samples was available, this concentration was used. If a child
was exposed to AED polytherapy, the mean normalized con-
centrations of each AED were added together.
Language delay
Global language delay
In Q3 and Q4, mothers completed a 3-item and a 6-item
version, respectively (data available from Dryad, table 1,
doi.org/10.5061/dryad.1237b6m), of the 18 months’ and 36
months’ communication scale from the Ages and Stages
Questionnaires (ASQ).24 ASQ is considered a reliable
screening tool with high concurrent validity.24,25 Each item
had the following answer options: yes (10 points), sometimes
(5 points), and not yet (0 points). The maximum score
reflecting no language delay was 30 and 60 points at 18 and 36
months, respectively. Children with missing answers in Q3
were excluded. If only 1 answer was missing in Q4, this was
imputed with the estimation-maximization procedure in SPSS
(IBM, Armonk, NY). Children were defined as having global
language delay when the mothers had reported an ASQ score
>1.5 SD below the mean ASQ score in the total MoBa
cohort.24,26
Expressive language delay
In Q4, a 1-item question regarding expressive language skills
has shown acceptable validity as an indicator of the gram-
matical complexity level of 3-year-old children (data available
from Dryad, table 2, doi.org/10.5061/dryad.1237b6m).27
The maximum score reflecting no expressive language delay
was 6 points. Children talking in 2- to 3-word phrases or less
were classified as having expressive language delay.
Figure 1 Flowchart of excluded and included cases
AED+ = antiepileptic drug use/exposure; AED− = no antiepileptic drug use/exposure.
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Covariates
Relevant covariates were selected from the MoBa ques-
tionnaires and from the MBRN6,28: parental higher education
(≥17 years of schooling), maternal low education (≤9 years of
schooling), total household income <400,000 Norwegian
kroner annually (equals approximately €42,000), unplanned
pregnancy, smoking and alcohol use (consumption ≥1 per
month) in pregnancy, parity (number of previous pregnancies
with >21 gestation weeks), maternal age, maternal depression
and anxiety symptoms during pregnancy (mean score >1.75 on
the Hopkins symptom checklist29 at gestational week 17–19),
single mother, maternal prepregnancy body mass index, seiz-
ures during pregnancy, tonic-clonic seizures during pregnancy
(data available from Dryad, Methods, doi.org/10.5061/dryad.
1237b6m), AED polytherapy, twin or triplet children, Apgar
score 5 minutes after birth, gestational age, and offspring sex.
Statistical analysis
The statistical analysis was performed with IBM SPSS software
version 24. AED-exposed and -unexposed children of mothers
with epilepsy were compared to a control group of children of
mothers without epilepsy. Each of the 3 groups was stratified by
periconceptional folic acid use. Groups with similar peri-
conceptional folic acid supplementation status were compared.
We also compared the supplemented group with the unsup-
plemented group within each of the 3 groups. Categorical vari-
ables were compared with the χ2 test for independence or Fisher
exact test when appropriate. Continuous variables were com-
pared with the Mann-WhitneyU test because of violation of the
assumption of normal distribution. The risk for delayed language
outcome was investigated with logistic regression. The re-
lationship between maternal plasma folate status/AED concen-
trations and language outcome was examined by a multivariable
linear regressionmodel and by correlation analysis. Values of p <
0.05 were considered statistically significant. We hypothesized
a causal relationship between no periconceptional folic acid
supplementation and language delay to calculate the attributable
risk (AR) of no periconceptional folic acid supplementation on
language delay in each of the 3 groups (data available from
Dryad, Methods, doi.org/10.5061/dryad.1237b6m). This was
done by calculating relative risk (RR) in a 2 × 2 table and then
the AR with the formula AR = RR − 1/RR.30
Standard protocol approval, registration, and
patient consent
The establishment and data collection in MoBa obtained
a license from the Norwegian Data Inspectorate and approval
from the Regional Committee for Medical Research Ethics.
The current study was approved by the Regional Committee
for Medical Research Ethics (reference No. 2011/1616).
Written informed consent was obtained from all participating
parents in MoBa.
Data availability
Data from MoBa and the MBRN used in this study are
managed by the national health register holders in Norway
and can be made available to researchers, provided that nec-
essary approval is obtained from the Regional Ethics Com-
mittees in Norway and from the data owners. The Norwegian
Institute of Public Health has a general contact point for data
access at the following e-mail address: datatilgang@fhi.no.
Results
Characteristics of the children, their parents, and the pregnancies
stratified by periconceptional folic acid use are presented in table
1 (full version: data available from Dryad, table 3, doi.org/10.
5061/dryad.1237b6m). A total of 268 children were exposed to
AED monotherapy in utero, and 65 children were exposed to
AED polytherapy (data available from Dryad, table 4). In chil-
dren exposed to monotherapy, the most frequently used AEDs
were lamotrigine (39%), carbamazepine (26%), valproate (15%),
levetiracetam (6%), topiramate (4%), and oxcarbazepine (3%).
In the polytherapy group, the most frequently used AEDs were
lamotrigine (51%), carbamazepine (32%), valproate (29%),
levetiracetam (29%), oxcarbazepine (23%), and topiramate
(15%). For 2 children, the AED drug regimen was unspecified.
Folic acid supplementation and language delay
Without periconceptional folic acid supplementation, 34% of
the AED-exposed children had global language delay at 18
months compared to 11% in the control group without ma-
ternal epilepsy (p < 0.001) (table 2). The fully adjusted odds
ratio (OR) was 3.9 (95% confidence interval [CI] 1.9–7.8, p <
0.001) (table 3). At 36 months, 24% of AED-exposed children
had expressive language delay compared to only 6% in the
control group (p < 0.001). The fully adjusted OR was 4.7 (95%
CI 2.0–10.6, p < 0.001). In the children of mothers who had
used folic acid periconceptionally, 17% of AED-exposed chil-
dren had global language delay at 18 months compared to 11%
in the control group (p = 0.01). The fully adjusted OR was 1.7
(95% CI 1.2–2.6, p = 0.01). For expressive language delay at 36
months with folic acid, 7% of AED-exposed children had a delay
compared to 4% in the control group (p = 0.08). The fully
adjusted ORwas 1.7 (95%CI 0.9–3.2, p = 0.13). There were no
significant differences between AED-unexposed children of
mothers with epilepsy and the control group (tables 2 and 3).
Within the group of AED-exposed children, the proportion of
children with language delay was higher in the no supplementa-
tion group than in the supplemented group (table 2). A difference
was also found in children of women without epilepsy, but it was
much smaller than for theAED-exposed children. Stratification by
AED revealed that the number of lamotrigine-exposed children
with language delay was significantly higher in the no supple-
mentation group compared to the supplemented group (table 4).
The same tendency was seen for children exposed to valproate
and carbamazepine, but this was not significant (table 4).
Mothers of AED-exposed children with language delay started
with folic acid later in pregnancy. The median start of folic
acid supplementation was gestational week 6.5 for AED-
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Children of mothers without
epilepsy
Periconceptional folic acida Periconceptional folic acida Periconceptional folic acida
Yes
(n = 260, 79%)
No
(n = 68, 21%)
Yes
(n = 289, 74%)
No
(n = 100, 26%)
Yes
(n = 77,929, 76%)
No
(n = 25,222, 25%)
Plasma folate,b median (minimum,
maximum), nmol/L
67.5 (11, 141) 67.6 (9, 117) — — — —
Gestational agec at birth, median
(minimum, maximum), wk
40.0 (16, 43) 39.0 (25, 42)k,p 39.0 (25, 43)n 39.0 (34, 42) 40.0 (16, 47) 40.0 (16, 47)r
Apgar score at 5 min, median
(minimum, maximum)
10.0 (0, 10) 9.5 (0, 10) 10.0 (0, 10) 9.5 (7, 10) 10.0 (0, 10) 10.0 (0, 10)
Maternal age, median (minimum,
maximum), y
29.0 (18, 42)j 30.0 (18, 38) 29.0 (19, 41)m 29.0 (16, 39) 30.0 (14, 47) 30.0 (14, 53)r
Single mother, n (%) 10 (4)j 5 (7) 8 (3) 9 (9)m,p 1,421 (2) 1,002 (4)r
Maternal higher education,d n (%) 42 (16)l 4 (6)p 43 (15)o 9 (9) 19,553 (25) 3,349 (13)r
Low total household income,e n (%) 27 (11)l 8 (13) 18 (6) 17 (19)n,r 4,126 (5) 2,342 (10)r
Unplanned pregnancy, n (%) 53 (21) 23 (34)p 57 (20) 33 (34)q 12,974 (17) 6,760 (27)r
Alcohol use,f n (%) 6 (2) 6 (9)j,p 5 (2) 4 (4) 1867 (2) 804 (3)r
Smoking, n (%) 24 (9)k 11 (16) 12 (4) 20 (20)r 4,116 (5) 3,380 (13)r
Anxiety/depression,g n (%) 52 (21)l 11 (17) 39 (14) 17 (18) 7,803 (10) 3,080 (13)r
TC seizure(s),h n (%) 17 (15) 3 (13) 3 (3) 2 (5) — —
AED polytherapy, n (%) 45 (17) 20 (29)p — — — —
Plasma AED,i median (minimum,
maximum), μmol/L
40.2 (0, 258) 33.0 (0, 159) — — — —
Valproate use, n (%) 42 (16) 14 (21) — — — —
Carbamazepine use, n (%) 68 (26) 22 (32) — — — —
Lamotrigine use, n (%) 108 (42) 27 (40) — — — —
Levetiracetam use, n (%) 30 (12) 5 (7) — — — —
Topiramate use, n (%) 16 (6) 3 (4) — — — —
Oxcarbazepine use, n (%) 17 (7) 7 (10) — — — —
Abbreviations: AED = antiepileptic drug; TC = tonic-clonic.
The number (n) may vary within the groups because of missing data. The χ2 test or Fisher exact test was used for comparing categorical variables; Mann-
Whitney U test was used for comparing continuous variables because of violation of the assumption of normal distribution. Clinical characteristics of parents
and children in the 2 epilepsy groups (children exposed and not exposed to AEDs) and the control group. All groups are stratified by periconceptional folic acid
supplementation.
a Use of folic acid supplementation 4 weeks before the start of the pregnancy and/or during the first trimester.
b Plasma folate concentration: sum of maternal 5-methyltetrahydrofolate and 4-alfa-hydroxy-5-methyl-tetrahydrofolate in plasma at gestational week 17 to
19.
c Calculated from the ultrasonographic measurements performed at 18 to 19 weeks of gestation. When ultrasound data were unavailable, gestational age
was estimated on basis of the first day of the last menstrual period.
d Seventeen or more years of schooling.
e Less than 400,000 Norwegian kroner (equals approximately €42,000) annually.
f Alcohol consumption ≥1 time per month during pregnancy.
g Maternal anxiety/depression during pregnancy (mean score >1.75 on the Hopkins symptom checklist in gestational week 17 to 19).
h N = 140 for AED-exposed children; n = 161 for AED-unexposed children.
i Median of standardized concentration (see text) in maternal plasma at gestational week 17 to 19 and umbilical cord blood.
Children ofmotherswith epilepsy using AED in pregnancy compared to children ofmotherswithout epilepsy stratified by folic acid use: jp < 0.05, kp < 0.01, and
lp < 0.001.
Children of mothers with epilepsy not using AED in pregnancy compared to children of mothers without epilepsy stratified by folic acid use: mp < 0.05, np <
0.01, and op < 0.001.
Children of mothers with no periconceptional folic acid supplement use compared to children of mothers with periconceptional folic acid supplement use
within each of the 3 groups (stratified by maternal epilepsy and AED exposure): pp < 0.05, qp < 0.01, and rp < 0.001.
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exposed children with language delay at 18 months and week
4.3 for AED-exposed children with language delay at 36
months. Mothers of AED-exposed children without language
delay most often started supplementation 3 weeks before
conception (p = 0.01 for 18 months and p = 0.05 for 36
months) (figure 2). When we analyzed supplementation in-
take in different gestational weeks, the proportion using folic
acid before the start of the pregnancy and during the first
trimester was higher for AED-exposed children without lan-
guage delay than in children with delay (figure 2).
The interaction between periconceptional folic acid use and
AED exposure after adjustment for relevant covariates was
significant for global language score at 18 months (p = 0.04)
and both global and expressive language score at 36months (p
< 0.001 and p = 0.01, respectively) (data available fromDryad,
figure 1, doi.org/10.5061/dryad.1237b6m). In AED-exposed
children, the AR of no periconceptional folic acid intake was 0.
51 for global language delay at 18 months and 0.52 at 36
months and 0.71 for expressive language delay at 36 months
without adjustment for covariates. In children of mothers
without epilepsy, the corresponding ARs were 0.06, 0.30, and
0.36. The ARs were similar after adjustment for relevant
covariates (data available from Dryad, table 5).There was no
significant relationship between language score and maternal
plasma folate concentrations (data available fromDryad, table
6 and figure 2A) or folic acid dose (≥1 mg [n = 84] vs 0.4 mg
[n = 55]) (data not shown) for AED-exposed children. Sen-
sitivity analyses were done with the mothers using valproate
or AED polytherapy excluded from the calculations. However,
the effects of folic acid on AED-related language delay were
similar or strengthened (data available from Dryad, table 7).
AED concentration and language delay
Higher maternal plasma valproate concentration was signifi-
cantly correlated with a lower global language score at age 18
months (r = −0.50, p = 0.04) (data available from Dryad,
figure 2, B and C, doi.org/10.5061/dryad.1237b6m). No
other significant correlations between language score and
maternal or umbilical cord AED concentrations were found
(data available from Dryad, table 8 and figure 2, A and C).
Discussion
We found that in AED-exposed children maternal periconcep-
tional folic acid supplementation was associated with better
language outcome compared to children of mothers not using
folic acid in the periconceptional period. The apparent pro-
tective effect of periconceptional folic acid supplementation was
striking in the AED-exposed children compared to the AED-
unexposed children of mothers with epilepsy and to children of
mothers without epilepsy. For all language outcomes, the ad-
justed ORs for language delay were lower for AED-exposed
children when folic acid supplementation was used compared
to no supplementation. The interaction analysis between
AED exposure and periconceptional folic acid use showed
a synergistic effect on the degree of language delay: no folic
acid supplementation had more consequences for language
scores in AED-exposed children than in children with no
AED exposure. The AR of no folic acid supplementation on
language delay was >50% in AED-exposed children, whereas
it was of modest importance in the control group.
Our results showing the importance of folic acid for language
development are in line with 2 studies that found higher mean
verbal index scores at 3 years and higher mean IQ at 6 years
age in AED-exposed children of periconceptionally folic
acid–supplemented mothers vs those without such
supplementation.9,10 We have recently found that peri-
conceptional folic acid supplementation and plasma folate
status in pregnancy also were associated with fewer autistic
Table 2 Children with language delay stratified by maternal periconceptional folic acid use
AED-exposed children of
mothers with epilepsy, n (%)
AED-unexposed children
of mothers with epilepsy,
n (%)
Children of mothers without
epilepsy, n (%)
Periconceptional folic acida Periconceptional folic acida Periconceptional folic acida
Language delay Yes No Yes No Yes No
Global language delay 18 mo 30 of 178 (17)b 13 of 38 (34)c,d 20 of 194 (10) 5 of 66 (8) 5,982 of 56,947 (11) 1856 of 16,659 (11)d
Global language delay 36 mo 8 of 143 (6) 4 of 34 (12) 9 of 162 (6) 3 of 42 (7) 2,275 of 45,437 (5) 858 of 11,930 (7)f
Expressive language delay 36 mo 10 of 144 (7) 8 of 33 (24)c,e 7 of 161 (4) 1 of 42 (2) 1844 of 45,536 (4) 753 of 11,931 (6)f
Abbreviation: AED = antiepileptic drug.
The χ2 test or Fisher exact testwas used for comparing categorical variables. Language delay in relation to periconceptional folic acid supplementation in the 2
epilepsy groups and in children of mothers without epilepsy. The epilepsy groups were compared to children of mothers without epilepsy and stratified by
periconceptional folic acid supplementation. Children of mothers with and without periconceptional folic acid supplementation were compared.
a Use of folic acid supplementation 4 weeks before the start of the pregnancy and/or during the first trimester.
Delayed language function in children ofmothers with epilepsy compared to children ofmotherswithout epilepsy stratified by folic acid use: bp < 0.01 and cp <
0.001.
Delayed language function in children ofmothers with no periconceptional folic acid supplement use compared to children ofmothers with periconceptional
folic acid supplement use within each of the 3 groups (stratified by maternal epilepsy and AED exposure): dp < 0.05, ep < 0.01, and fp < 0.001.
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traits in AED-exposed children from the same epilepsy co-
hort.13 A modest effect of folic acid supplementation on risk
of autism was also seen in children of mothers without epi-
lepsy.8 However, other studies did not find an association
between folic acid supplementation and child IQ,12 verbal
comprehensive intelligence,11 or general language function in
AED-exposed children.31,32 The discrepancy could be due to
type of AED exposure and the timing or dose of folic acid
supplementation. In addition, different folic acid food forti-
fication practices between countries could blur the association
between folic acid supplement and language outcome. Al-
though there is some overlap between autism and language
delay, language delay is multifactorial, complex, and much
more common than autism.33–35We thus believe only a minor
amount of the language delay found in our study might have
been attributed to autistic traits.
We found that the critical period for maternal folic acid
supplementation to prevent language delay in AED-exposed
children was from 4 weeks before the start of the pregnancy
and until the end of the first trimester. There was no signifi-
cant association between language delay and folic acid sup-
plementation later in pregnancy. Previous studies in the
general population similarly highlight the periconceptional
period for folic acid supplementation to prevent language
delay.3,6
The larger proportion of language delay in lamotrigine-
exposed children with no folic acid supplementation com-
pared to those with supplementation has not been reported
previously. However, mean IQ was higher in lamotrigine-
exposed children who had been supplemented with folic acid
compared to those who had not.9 In rodents given lamo-
trigine, folic acid supplementation improved their epilepsy,
mood, and memory.36 Low serum folate concentrations have
been reported after lamotrigine therapy.37 Impaired neuro-
development after lamotrigine exposure in utero has been
discussed, but data have been conflicting.38,39 A particularly
Table 3 Crude and adjusted ORs (95% CIs) for language delay in children of mothers with epilepsy stratified by
periconceptional folic acid use
AED-exposed children of mothers with epilepsy AED-unexposed children of mothers with epilepsy
Periconceptional folic acida Periconceptional folic acida
Yes No Yes No
Global language delay 18 mo
Crude 1.7 (1.2–2.6)b 4.1 (2.1–8.1)c 1.0 (0.6–1.6) 0.7 (0.3–1.6)
Adjusted model 1 1.7 (1.1–2.5)b 4.2 (2.1–8.2)c 0.9 (0.6–1.5) 0.7 (0.3–1.7)
Adjusted model 2 1.7 (1.2–2.6)b 4.4 (2.2–8.7)c 1.0 (0.6–1.5) 0.7 (0.3–1.8)
Adjusted model 3 1.7 (1.2–2.6)b 3.9 (1.9–7.8)c 0.9 (0.6–1.5) 0.7 (0.3–1.7)
Global language delay 36 mo
Crude 1.1 (0.6–2.3) 1.7 (0.6–4.9) 1.1 (0.6–2.2) 1.0 (0.3–3.2)
Adjusted model 1 1.1 (0.5–2.2) 1.8 (0.6–5.1) 1.1 (0.6–2.1) 1.0 (0.3–3.3)
Adjusted model 2 1.1 (0.5–2.2) 1.8 (0.6–5.2) 1.1 (0.6–2.2) 1.0 (0.3–3.3)
Adjusted model 3 1.1 (0.5–2.2) 1.6 (0.6–4.7) 1.1 (0.5–2.1) 1.1 (0.3–3.5)
Expressive language delay 36 mo
Crude 1.8 (0.9–3.4) 4.8 (2.1–10.6)c 1.1 (0.5–2.3) 0.4 (0.1–2.6)
Adjusted model 1 1.7 (0.9–3.2) 5.0 (2.2–11.3)c 1.0 (0.5–2.2) 0.4 (0.0–2.6)
Adjusted model 2 1.7 (0.9–3.2) 5.1 (2.3–11.5)c 1.1 (0.5–2.3) 0.4 (0.0–2.6)
Adjusted model 3 1.7 (0.9–3.2) 4.7 (2.0–10.6)c 1.0 (0.5–2.2) 0.4 (0.1–2.8)
Abbreviation: AED = antiepileptic drug; CI = confidence interval; OR = odds ratio.
The full model containing all predictors (adjusted model 3) was statistically significant (p < 0.0001) for all language outcomes stratified by periconceptional
folic acid supplementation. Covariates in the adjustedmodels: model 1:maternal age, parental socioeconomic status (singlemother, lowmaternal education
[≤9 years], low household income [<400,000 Norwegian kroner, equals approximately €42,000 per year]), parity (prior pregnancies >21 gestation weeks),
smoking during pregnancy, alcohol use (consumption ≥1 time permonth) during pregnancy, andmaternal anxiety/depression symptoms (mean score >1.75
on the Hopkins symptom checklist in gestational week 17 to 19) during pregnancy; model 2: all covariates inmodel 1 plus maternal prepregnancy bodymass
index; and model 3: all covariates in models 1 and 2 plus Apgar score at 5 minutes after birth and gestational age (calculated from the ultrasonographic
measurements performed at 18 to 19 weeks of gestation. When ultrasound data were unavailable, gestational age was estimated on basis of the first day of
the last menstrual period). Crude and adjusted ORs [95% CIs]) for language delay in children of mothers with epilepsy compared to children of mothers
without epilepsy stratified by periconceptional folic acid supplementation.
a Use of folic acid supplementation 4 weeks before the start of the pregnancy and/or during the first trimester.
Children of mothers with epilepsy compared to children of mothers without epilepsy stratified by folic acid use: bp < 0.01 and cp < 0.001.
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Table 4 Delayed language function with and without periconceptional folic acid supplementation for various AEDs




Global language delay 18 mo 9 of 30 (30) 2 of 6 (33)
Global language delay 36 mo 4 of 27 (15) 0 of 5 (0)
Expressive language delay 36 mo 4 of 27 (15) 1 of 4 (25)
Lamotrigine
Global language delay 18 mo 13 of 77 (17) 7 of 16 (44)b
Global language delay 36 mo 4 of 58 (7) 2 of 16 (13)
Expressive language delay 36 mo 3 of 59 (5) 6 of 16 (38)c
Levetiracetam
Global language delay 18 mo 3 of 21 (14) 0 of 2 (0)
Global language delay 36 mo 1 of 21 (5) 0 of 2 (0)
Expressive language delay 36 mo 2 of 21 (10) 0 of 1 (0)
Topiramate
Global language delay 18 mo 2 of 9 (22) 0 of 2 (0)
Global language delay 36 mo 0 of 6 (0) 0 of 2 (0)
Expressive language delay 36 mo 1 of 5 (20) 0 of 1 (0)
Oxcarbazepine
Global language delay 18 mo 5 of 12 (42) 1 of 5 (20)
Global language delay 36 mo 1 of 10 (10) 1 of 4 (25)
Expressive language delay 36 mo 1 of 10 (10) 1 of 4 (25)
Carbamazepine
Global language delay 18 mo 4 of 43 (9) 3 of 12 (25)
Global language delay 36 mo 0 of 34 (0) 1 of 11 (9)
Expressive language delay 36 mo 1 of 34 (3) 1 of 11 (9)
AED monotherapy
Global language delay 18 mo 22 of 149 (15) 9 of 28 (32)
Global language delay 36 mo 6 of 120 (5) 3 of 23 (13)
Expressive language delay 36 mo 8 of 121 (7) 6 of 23 (26)b
AED polytherapy
Global language delay 18 mo 8 of 28 (29) 3 of 9 (33)
Global language delay 36 mo 2 of 22 (9) 1 of 10 (10)
Expressive language delay 36 mo 2 of 22 (9) 2 of 9 (22)
Abbreviation: AED = antiepileptic drug.
The χ2 test or Fishes exact test was used for comparing categorical variables. The number of children exposed to each AED includes both monotherapy and
polytherapy treatment.
a Use of folic acid supplementation 4 weeks before the start of the pregnancy and/or during the first trimester.
Delayed language function in children ofmothers with no periconceptional folic acid supplement use compared to children ofmothers with periconceptional
folic acid supplement use stratified by maternal epilepsy (and specific AED exposure): bp < 0.05 and cp < 0.01.
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beneficial effect of periconceptional folic acid supplementa-
tion on language function in lamotrigine-exposed children is
possible and could explain previous discordant results.
We did not find any correlation between folic acid doses or
plasma folate concentrations and language delay. The ma-
ternal plasma samples were obtained during gestational week
17 to 19, which may not reflect accurately the folic acid
supplement use reported before and very early in the preg-
nancy.40 The exact dose of folic acid recommended to women
with epilepsy who use AEDs has not been established.2 The
safety of high-dose folic acid supplement use in women with
epilepsy and in the general population is still debated.41,42
Folic acid dose recommendations cannot yet be specified for
individual AEDs, although several AEDs interact with folic
acid metabolism.4,5,37
Figure 2 Relationship between language delay and timing of maternal folic acid intake
Graphs illustrate the proportion of children (percent)
exposed to maternal folic acid supplementation at dif-
ferent time intervals during pregnancy and the re-
lationship to language delay (orange lines) and no
language delay (green lines) at 18 and 36 months. Lan-
guage delay at 36months includes global language delay
and expressive language delay. Arrows illustrate median
start and median stop of maternal folic acid supple-
mentation during pregnancy. Significant differences in
folic acid supplementation (χ2 test for independence)
and median start/stop of folic acid supplementation
(Mann-Whitney U test) are marked with asterisks. (A)
Antiepileptic drug (AED)–exposed children of mothers
with epilepsy at 18 months (n = 216) and 36 months (n =
179). (B) AED–unexposed children of mothers with epi-
lepsy at 18 months (n = 260) and 36 months (n = 204). (C)
Children of mothers without epilepsy at 18 months (n =
73,606) and 36 months (n = 57,715). Statistically signifi-
cant differences were seen even with minor or no dif-
ferences in percentages (p values between 0.02 and 0.05)
or medians because of a high number of observations.
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We found a correlation between high maternal plasma val-
proate concentrations and low language score in children 18
months of age. This is in line with previous data showing
a dose-dependent increased risk of language delay after val-
proate exposure in utero.38,43,44 Maternal drug dose has been
used as a proxy for child exposure, but valproate use in women
of childbearing age has shown an extensive interindividual
pharmacokinetic variability, with dose being a poor reflector
of concentration.45
Strengths of our study are a large data collection including 2
different epilepsy groups. Both the maternal diagnosis of ep-
ilepsy and the type of AEDs have been validated. Maternal
plasma folate and AED concentrations in umbilical cord and
maternal blood were measured. Selection bias in the MoBa is
moderate and does not affect exposure-outcome association
analysis.46 We adjusted for relevant confounders. Sensitivity
analyses confirmed that the association of no use of folic acid
with delayed language was not confounded by the frequency
of polytherapy or valproate users. Our data have been
obtained from parental reporting, and the interobserver re-
liability between parents and professional examiners for ASQ
has been validated as high.24 Parents are good evaluators of
language abilities of their children.47
Weaknesses of our study include relatively low numbers of
children exposed to specific AEDs and different doses of folic
acid. This limits the interpretation of folate effects linked to
individual AEDs and the effects of AED concentrations on
language development; both are areas for future research.
There were some loss to follow-up at 18 and 36 months of
age. We do not have data on language development in the
nonresponding group and do not know whether language
delay in the child influenced the mother’s motivation for
continued participation. None of the children were assessed
blindly because the language delay relied on maternal report
only, not on a formal neuropsychologist review. Although the
participants were included from 1999 to 2008 when less was
known about the potential harmful effects of AEDs on lan-
guage development, mothers who used AEDs during the
pregnancy might have been more vigilant when reporting
language skills than mothers with epilepsy not using AEDs.
The mothers reported folic acid use before pregnancy during
gestational week 17 to 19, and this may have an effect on the
accuracy of these estimates. We do not have data on parental
IQ or familial risk of language delay and therefore could not
adjust for these factors in our analyses. Plasma folate con-
centrations were not measured at the most critical point for
child development. The lack of mandatory folic acid fortifi-
cation in Norway may have accentuated our results. Thus, our
findings may not be generalizable to countries with a manda-
tory folic acid food fortification practice.
We found an apparent extensive protective effect of maternal
folic acid supplementation from 4weeks before the start of the
pregnancy and during the first trimester on language delay at
age 18 and 36 months in AED-exposed children of mothers
with epilepsy. This effect was much stronger in AED-exposed
children compared to children of mothers without epilepsy
because no folic acid supplementation had more con-
sequences for language scores in AED-exposed children
compared to children not exposed to AEDs. From these
findings, we advocate daily folic acid intake in all women on
AEDs who are likely to become pregnant to decrease the risk
of AED-mediated language delay.
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